Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Human Genome Sciences    HGSI   US4449031081

SummaryQuotesChart AnalysisNews 

Human Genome Holder Says Glaxo Bid "Unacceptable" - Newspaper

04/29/2012 | 09:22am US/Eastern

A fund with a 5.6% stake in Human Genome Sciences Inc. (>> Human Genome Sciences), the U.S. drug company for which GlaxoSmithKline PLC (>> GlaxoSmithKline plc) has made an unsolicited $2.6 billion offer, said the approach is "unacceptable", according to the Sunday Times.

Human Genome Sciences, based in Rockville, Md., on April 20 rejected Glaxo's $13 a share offer, which it said undervalues the company.

Taube Hodson Stonex, a London-based fund, said the offer amounted to Glaxo trying to "get a steal with an offer that completely undervalues the company", the Sunday Times reports, attributing the remarks to Taube Hodson Stonex's Mark Evans.

"Towards $20 per share would still feel undervalued," Evans is quoted as saying.

THS couldn't be reached for comment Sunday.

Glaxo and Human Genome Sciences have a long working relationship, co-leveloping and sharing profits on Benlysta, a lupus medicine.

Newspaper Web site:

-London Bureau, Dow Jones Newswires; +44 (0)20 7842 9320

Stocks mentioned in the article : Human Genome Sciences, GlaxoSmithKline plc
Recommend :
React to this article
03/31 GLAXOSMITHKLINE : GSK CEO says success of heart drug 'an open question'
03/31DJGLAXOSMITHKLINE : Glaxo Details Results of Disappointing Heart-Disease Drug Stud..
03/30 GLAXOSMITHKLINE : Study shows Glaxo heart drug which failed trial has potential ..
2013 MORGAN STANLEY : Convicted ex-FrontPoint manager ordered to repay Morgan Stanley
2013DJBayer Raises Algeta Bid to $2.87 Billion
2013 GLAXOSMITHKLINE PLC : GlaxoSmithKline heart drug misses goal in major study
2013 Crunch time for GlaxoSmithKline's big heart drug bet
2012 HUMAN GENOME SCIENCES : Announces required offer to repurchase in respect of its..
2012DJGlaxoSmithKline Completes Acquisition of Human Genome Sciences
2012DJGlaxoSmithKline Gets 79% Tenders for Human Genome Sciences Offer
Duration : Period :
Human Genome Sciences Technical Analysis Chart | HGSI | US4449031081 | 4-Traders
Dynamic quotes